RARB and lung carcinoma: In clinical practice, many of these DMRs have the potential to predict disease progression, including in patients with stage IV lung cancer (SHOX2, RARB/RASSF1A, RARB, RASSF1A/APC, DCLK1, BRMS1, SOX17, SFN, CHFR, and APC/RASSF1A/CDH13/CDKN2A) [109].